Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
121
mentions
- News 54
- X 49
- Blogs 8
- Bluesky 3
- +3 more

